A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV — SHINY  

Choroid Neovascularization Secondary to Degenerative Myopia Clinical Trial

Official title: The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia

Status Active, not recruiting

Clinical Trial Summary

This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Choroid Neovascularization Secondary to Degenerative Myopia
• Choroidal Neovascularization
• Myopia
• Myopia, Degenerative
• Neovascularization, Pathologic

• NCT number: NCT01809223
• Study type: Interventional
• Source: Chengdu Kanghong Biotech Co.,Ltd.
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 2012
• Completion date: March 2015